By PPN News Staff
The FDA approved daunorubicin-cytarabine (Vyxeos, Jazz Pharmaceuticals) to treat adults with two types of acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Designed with Jazz’s CombiPlex proprietary technology, Vyxeos is a unique liposomal formulation that delivers a fixed ratio of daunorubicin and cytarabine to the bone marrow that has been shown to have synergistic effects at killing leukemia